Unswitch-ABL Drugs Overcome Resistance in Chronic Myeloid Leukemia  by Packer, Leisl & Marais, Richard
Cancer Cell
Previewssystem. For instance, the chemokine
receptors CXCR4 and CCR5 interact
with gp120, acting as HIV coreceptors
and the chemokine CXCL16 interacts
with oxidized LDL. Chemokine receptors
can also form heterodimers with other
chemokine receptors (Thelen et al.,
2010) or with other membrane receptors
modulating their function. For instance,
CXCR2 and CXCR4 interacting with
CD74 become functional receptors for
the noncanonical chemokine macro-
phage migration inhibitory factor (MIF),
and one could entertain the possibility
that PITPNM3 forms a dimer with
a conventional signaling GPCR.
Previous studies (Soria and Ben-Bar-
uch, 2008) have shown that levels of
the monocyte-attracting chemokines
CCL2 and CCL5 are associated with
macrophage infiltration and prognosis.
Therefore, a comprehensive ‘‘chemoki-
nome’’ system biology perspective may
well be required to explore the clinical
significance of chemokine levels in
cancer.The results reported here shed new
light on the role of chemokines in cancer
and raise important questions. There is
no mouse counterpart of CCL18 on which
to rely for rigorous genetic approaches to
investigate its role in carcinogenesis.
CCL18 was found in other human
tumors, ovarian in particular. The present
findings call for an appraisal of its prog-
nostic significance in these pathologies.
The actual structure of the CCL18-recog-
nizing receptor complex will also need to
be further investigated. Finally, and no
less important, chemokine anticancer
therapeutic strategies have entered clin-
ical evaluation. In spite of stumbling
blocks (e.g., lack of mouse counterpart,
drugability of the receptor), CCL18 may
be added to the list of potential thera-
peutic targets.REFERENCES
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ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-
ABLT315I mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer
Cell, that ‘‘switch-control’’ inhibitors block BCR-ABLT315I activity by preventing ABL from switching from the
inactive to active conformation.The BCR-ABL fusion protein is the
primary driver oncogene in the majority
of chronic myeloid leukemias (CML) and
also in about 25% of adult acute lympho-
blastic leukemias (ALL) (Druker et al.,
2001). This protein is expressed from a
fusion gene resulting from a reciprocal
translocation between chromosome 9
and 22 (t(9;22)(q34;q11)), the so-called
Philadelphia chromosome (Ph+). ABL
is a tyrosine kinase and its fusion toBCR causes constitutive activation,
driving hematopoietic cell transformation
through activation of multiple signaling
pathways. The treatment of CML was
revolutionized by the development of ima-
tinib, a small molecular-weight drug that
inhibits ABL and mediates durable hema-
tologic and cytologic responses in CML
patients. The importance of imatinib
cannot be underestimated, because as
the first tyrosine kinase inhibitor (TKI) toachieve responses in cancer patients, it
provided a paradigm shift in cancer
treatment.
Although imatinib changed the clinical
management of CML, some patients
eventually fail on therapy due to acquired
resistance. Resistance can be mediated
by secondary mutations in BCR-ABL
that block imatinib binding through steric
hindrance or by switching ABL into the
active conformation. Like imatinib, thel 19, April 12, 2011 ª2011 Elsevier Inc. 435
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nilotinib (Weisberg et al., 2007) and dasa-
tinib (Shah et al., 2004) are also ATP-
competitive inhibitors but are more potent
and so retain binding to the majority of
imatinib-resistant BCR-ABL mutants.
Further, whereas imatinib only binds to
the inactive conformation of ABL (type II
inhibition), dasatinib binds both the active
(type I inhibition) and inactive conforma-
tions, overcoming mutations that stabilize
the active conformation.
Nilotinib and dasatinib provide vital
second-line treatments for the majority of
CMLpatientswho relapsebecauseofpoint
mutations that block imatinib binding to
BCR-ABL. However, a relatively common
mutant, the T315I or ‘‘gatekeeper’’ muta-
tion, is resistant to all three drugs (Gorre
et al., 2001; Shah et al., 2004; Weisberg
et al., 2007) because it not only stabilizes
the active conformation of ABL to block
imatinib and nilotinib binding, but also
introduces a steric clash with dasatinib in
theATPpocket. Furthermore,bystabilizing
the active conformation of ABL, T315I also
mediates resistance to allosteric inhibitors
(type III inhibitors) such as GNF2 or GNF5,
because although they bind to BCR-
ABLT315I they do not block its activity.
Thus, T315I represents a persistent
clinical problem that accounts for 15%–
20% of imatinib-resistant mutants.
To develop novel inhibitors of BCR-
ABLT315I, Chan et al. (2011) used struc-
ture-based drug design to create com-
pounds that bind to the so-called ‘‘switch
control’’ amino acids of ABL. In many
kinases, activation is initiated by events
such as phosphorylation, but their ability
to switch between the inactive and active
conformations is controlled by the switch
control amino acids, which manage the
thermodynamic, electrostatic, and pH
changes that are needed to allow amino
acid movements within the confines of
the kinase domain. Critically, switch
control amino acids adopt distinct orien-
tations in the active and inactive confor-
mation of the kinase and ‘‘switch-control
inhibitors’’ are designed to stabilize their
inactive orientation and lock the kinase
in its inactive conformation.
By comparing the active and inactive
conformations of ABL and LCK, Chan
et al. (2011) identified R386 of ABL
as a critical switch control amino acid.
With this knowledge, they designed dia-
rylureas to target this region and finally436 Cancer Cell 19, April 12, 2011 ª2011 Elsproduced DCC-2036. Using structural
approaches, Chan et al. show that
DCC-2036 locks BCR-ABL in the inac-
tive conformation even when it is phos-
phorylated on the activation site Y393.
More importantly, they show that DCC-
2036 also locks BCR-ABLT315I into the
inactive conformation. Thus, by targeting
the switch pocket, DCC-2036 can over-
come resistance that is mediated by
mutations that lock ABL in the active
conformation and also by those that
introduce steric clashes in the ATP-
binding pocket.
DCC-2036 is a potent ABL inhibitor
(IC500.75 nM), but it does display rather
broad activity and inhibits many other
kinases, including TIE2, FLT3, and several
SRC family kinases. Highly selective in-
hibitors are extremely valuable for proof-
of-principle studies and they satisfy our
purist ideas about the importance of
inhibiting single targets with individual
drugs. However, broad specificity drugs
can achieve impressive responses in pa-
tients, not least because targeting several
kinases simultaneously may mediate
additive responses. In this context, the
inhibition of SRC family kinases by DCC-
2036 may provide unforeseen clinical
benefits in CML patients. Furthermore,
multikinase inhibitors can show efficacy
is several indications, so the broad
specificity of DCC-2036 may not be a
disadvantage, but its advantages will
need to be balanced against the possi-
bility of increased mechanism-based
and off-target toxicities.
Chan et al. (2011) show that DCC-2036
inhibits BCR-ABL and blocks phosphory-
lation of its substrates STAT5 and Crkl in
CML, and Ph+ ALL cell lines. In mice,
DCC-2036 has excellent oral bioavail-
ability, easily reaching blood plasma
levels above its predicted active concen-
tration. It is well tolerated and does not
appear to affect normal hematopoietic
cells. Critically, it prolongs mouse survival
in BCR-ABLT315I CML and ALL models.
DCC-2036 is currently undergoing Phase
I clinical trials, and preliminary data
show that it mediates a striking reduction
in phospho-STAT5 in the cells from
patients treated with 300mg. It also medi-
ates a minor reduction in phospho-Crkl in
BCR-ABLT315I CML cells in patients
treated with 100mg DCC-2036. While it
is unclear how these effects will translate
to tumor response, its ability to inhibitevier Inc.both ‘‘wild-type’’ and mutant BCR-ABL
in patients is extremely promising.
DCC-2036 is not the first drug to show
activity against leukemias harboring BCR-
ABLT315I. Following promising Phase I
results, the potent BCR-ABL and BCR-
ABLT315I inhibitor ponatinib (AP24534;
O’Hare et al., 2009) is currently undergoing
Phase II clinical trials in CML and Ph+ ALL
patients who are resistant or intolerant to
nilotinib and dasatinib. HG-7-85-01
combines features of imatinib and dasati-
nib and has anti-BCR-ABLT315I activity,
particularly when combined with nilotinib
(Weisberg et al., 2010), and although the
allosteric inhibitors GNF2 and GNF5 lack
intrinsic anti-BCR-ABLT315I activity, at
high concentrations they are active when
combinedwithnilotinib (Zhangetal., 2010).
These continue to be exciting times in
CML research, and it seems probable
that one or more of these third-generation
drugs will show clinical efficacy against
BCR-ABLT315I. An optimist may wonder if
the final chapter of the CML story is now
being written, but this seems unlikely. The
lastdecadehasshown thatCML isextraor-
dinarily adaptable and appears to escape
new treatments with relative ease.
It may therefore be pertinent to con-
sider how the cells will escape drugs
such as DCC-2036. Clues to the answer
may already be available. Although rare,
compound BCR-ABL mutants harboring
more than one point mutation have been
described in patients sequentially treated
with ABL inhibitors (Shah et al., 2007).
Where these include the T315I mutation,
the compound mutants exhibit greater
resistance to TKIs than the T315I single
mutation. It would be interesting to know
how sensitive these compound mutants
are to DCC-2036. It should also be re-
membered that only 60% of CML resis-
tance is mediated by BCR-ABL-depen-
dent mechanisms, so resistance to
switch control drugs may generally be
driven by BCR-ABL-independent mecha-
nisms. Again, it would be interesting to
test this broad specificity drug against
cells whose resistance is BCR-ABL inde-
pendent. Presumably, if resistance is
mediated by DCC-2036 targets such as
the SRC family kinases (Donato et al.,
2003), sensitivity will be retained.
However, other mechanisms may provide
resistance, such as mutations in the
switch control amino acids. Finally, it
remains unclear if any of these
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Previewscompounds target the stem cell popula-
tion effectively. This is important because
these cells are thought to be the source of
the residual disease that remains even
after long-term drug treatment.
If it lives up to its promise, DCC-2036
will play a role in the CML and AML
stories. Regardless of its final contribution
to the clinical management of these
diseases, switch control drugs are
certainly a very elegant solution to the
BCR-ABLT315I problem.
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Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance
is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by
which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic
workarounds.Paul Simon famously sang about the fifty
ways to leave your lover. Two recent
studies by Sequist et al. (2011) and Bivona
et al. (2011) have revealed several addi-
tional new ways by which non-small cell
lung cancers (NSCLC) can escape the
clutches of small molecule inhibitors of
the epidermal growth factor receptor
(EGFR) tyrosine kinase. Whether there
will turn out to be fifty, or even more
mechanisms through which resistance
can be mediated—either de novo or
acquired during treatment—remains to
be seen. What is clear is that there are
a growing number of ingenious molecular
means by which cancers can circumvent
inhibitors of EGFR and other oncogenic
kinases. Although representing thera-
peutic challenges to the clinician, thesemechanisms also suggest rational new
therapeutic opportunities to improve clin-
ical outcomes. Furthermore, by using
kinase inhibitors as chemical probes
(Workman and Collins, 2010) to interro-
gate human cancers, we are gaining
considerable fundamental as well as
translational insights into the diverse
mechanisms of human oncogenesis.
The extraordinary success of imatinib in
prolonging the lives of patients with
chronic myeloid leukemia (CML) through
the inhibition of the pathogenic tyrosine
kinase activity of BCR-ABL has had
a major scientific impact in validating the
concept of single kinase addiction in the
clinic (Druker et al., 2006). Furthermore,
the principle of treating such oncogene
addiction (Weinstein, 2002) with inhibitorsof the respective major driver kinases has
proved to be applicable to many other
types of cancer. On the other hand, the
tumor regression and prolonged survival
obtained are commonly not as sustained
as in CML (Sawyers, 2009).
NSCLC is a leading cause of deathworld-
wide (www.who.int/cancer/en/, http://
globocan.iarc.fr/factsheets/populations/
factsheet.asp?uno=900), and cytotoxic
chemotherapy has limited effectiveness.
Approximately 10% of NSCLCs in
western populations harbor somatic
mutations in exons encoding the tyrosine
kinase domain of EGFR, and these occur
with an increased frequency in adenocar-
cinomas arising in nonsmokers, females,
and individuals of Asian ethnicity. These
mutations cause activated signalingl 19, April 12, 2011 ª2011 Elsevier Inc. 437
